# Specifying the Anti-inflammatory Effects of Ziltivekimab

> **NCT06263244** · PHASE3 · RECRUITING · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 40 (estimated)

## Conditions studied

- Atherosclerosis
- Inflammation

## Interventions

- **DRUG:** Ziltivekimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06263244
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-03
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06263244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06263244, "Specifying the Anti-inflammatory Effects of Ziltivekimab". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06263244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*